Mink Financial Statements From 2010 to 2024

INKT Stock  USD 0.98  0.02  1.98%   
Mink Therapeutics financial statements provide useful quarterly and yearly information to potential Mink Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Mink Therapeutics financial statements helps investors assess Mink Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Mink Therapeutics' valuation are summarized below:
Market Capitalization
39.2 M
Earnings Share
(0.59)
There are currently one hundred twenty fundamental ratios for Mink Therapeutics that can be evaluated and compared over time across peers in the industry. All traders should check Mink Therapeutics' last-minute fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction.
Check Mink Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mink Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 584.4 K, Depreciation And Amortization of 256.1 K or Interest Expense of 216.6 K, as well as many indicators such as Price To Sales Ratio of 0.0355, Dividend Yield of 0.0 or Days Sales Outstanding of 134. Mink financial statements analysis is a perfect complement when working with Mink Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Mink Therapeutics Correlation against competitors.
For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.

Mink Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.3 M4.6 M5.9 M
Slightly volatile
Short and Long Term Debt Total38.8 M50.4 M32.6 M
Slightly volatile
Other Current Liabilities8.6 M7.5 M3.2 M
Slightly volatile
Total Current Liabilities13.7 M11.4 M9.5 M
Slightly volatile
Other Liabilities327.5 K344.8 K2.4 M
Slightly volatile
Property Plant And Equipment Net764.8 K954 K517.1 K
Slightly volatile
Current Deferred Revenue152.8 K171.9 K187.2 K
Slightly volatile
Accounts PayableM3.9 MM
Slightly volatile
Cash3.2 M3.4 M4.7 M
Slightly volatile
Non Current Assets Total764.8 K954 K517.1 K
Slightly volatile
Long Term Debt38.8 M50.4 M32.6 M
Slightly volatile
Cash And Short Term Investments3.2 M3.4 M4.7 M
Slightly volatile
Net Receivables19.7 K20.7 K218.4 K
Slightly volatile
Common Stock Shares Outstanding36.9 M34.4 M33.5 M
Slightly volatile
Liabilities And Stockholders Equity4.3 M4.6 M5.9 M
Slightly volatile
Non Current Liabilities Total15.7 M11.2 M25.7 M
Slightly volatile
Inventory1.5 K1.6 K127.6 K
Very volatile
Other Current Assets438.2 K231.1 K290.8 K
Slightly volatile
Other Stockholder Equity73.6 M115.8 M27.4 M
Slightly volatile
Total Liabilities25.1 M22.6 M34.7 M
Slightly volatile
Property Plant And Equipment GrossM1.4 M627.2 K
Slightly volatile
Total Current Assets3.4 M3.6 M5.4 M
Slightly volatile
Capital Stock331346267
Slightly volatile
Non Current Liabilities Other45.7 K48.1 K3.5 M
Very volatile
Short Term Debt3.8 M4.3 M4.7 M
Slightly volatile
Common Stock331346267
Slightly volatile
Property Plant Equipment693.7 K1.2 M530.5 K
Slightly volatile
Common Stock Total Equity271305332
Slightly volatile
Capital Surpluse88.7 M99.7 M108.6 M
Slightly volatile
Other Assets0.80.90.98
Slightly volatile

Mink Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization256.1 K204.6 K171.8 K
Slightly volatile
Interest Expense216.6 K228 K1.4 M
Slightly volatile
Selling General Administrative5.5 M7.4 M4.3 M
Slightly volatile
Other Operating Expenses23.5 M22.9 M22.8 M
Very volatile
Research Development18 M15.5 M18.4 M
Slightly volatile
Total Operating Expenses23.4 M22.7 M22.8 M
Very volatile
Reconciled Depreciation105.7 K189 K61.2 K
Slightly volatile
Cost Of Revenue194.4 K204.6 KB
Slightly volatile
Interest Income394.1 K463.3 K276.7 K
Slightly volatile
Non Operating Income Net Other2.2 M2.4 M2.7 M
Slightly volatile
Selling And Marketing Expenses5.9 B6.7 B7.3 B
Slightly volatile

Mink Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings8.5 M8.5 M10.8 M
Slightly volatile
Stock Based CompensationM3.9 M858.8 K
Slightly volatile
Begin Period Cash Flow14.5 M19.6 MM
Slightly volatile
Depreciation109.2 K204.6 K62.4 K
Slightly volatile
Capital Expenditures69.9 K73.6 K333.5 K
Slightly volatile
Change To Account Receivables2.1 M1.6 M2.9 M
Slightly volatile
Change To Operating ActivitiesM3.5 M5.3 M
Slightly volatile
End Period Cash Flow3.2 M3.4 M4.7 M
Slightly volatile
Change To Netincome6.7 M3.5 M3.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.03550.0374384
Slightly volatile
Days Sales Outstanding134151164
Slightly volatile
Average Payables3.3 M4.9 M3.3 M
Slightly volatile
Stock Based Compensation To Revenue0.00120.00130.2127
Slightly volatile
EV To Sales0.02760.029409
Slightly volatile
Inventory Turnover15.2 M14.5 M4.1 M
Slightly volatile
Days Of Inventory On Hand0.00.0K
Slightly volatile
Payables Turnover0.04970.0523985
Slightly volatile
Sales General And Administrative To Revenue0.00320.00333.7016
Slightly volatile
Average Inventory962K413.3 K
Slightly volatile
Research And Ddevelopement To Revenue0.00930.009819.0028
Slightly volatile
Cash Per Share0.09310.0980.1405
Slightly volatile
Capex To Operating Cash Flow0.00440.00470.0226
Slightly volatile
Days Payables Outstanding7.6 KK16.2 K
Slightly volatile
Income Quality0.470.70190.6042
Slightly volatile
Current Ratio0.30.31560.4105
Slightly volatile
Receivables Turnover1.741.962.1321
Slightly volatile
Graham Number3.322.77993.8682
Slightly volatile
Revenue Per Share75.9172.2925.9587
Slightly volatile
Interest Debt Per Share0.00820.00870.7668
Slightly volatile
Debt To Assets18.5511.0619.9666
Slightly volatile
Days Of Payables Outstanding7.6 KK16.2 K
Slightly volatile
Ebt Per Ebit1.130.97981.058
Pretty Stable
Quick Ratio0.280.29530.3672
Slightly volatile
Dividend Paid And Capex Coverage Ratio22521466.9487
Slightly volatile
Net Income Per E B T1.020.88531.0362
Slightly volatile
Cash Ratio0.280.29530.3385
Slightly volatile
Days Of Inventory Outstanding0.00.0K
Slightly volatile
Days Of Sales Outstanding134151164
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.00471.0303
Pretty Stable
Fixed Asset Turnover2.4 K2.3 K820
Slightly volatile
Capital Expenditure Coverage Ratio22521466.9487
Slightly volatile
Debt Ratio18.5511.0619.9666
Slightly volatile
Price Sales Ratio0.03550.0374384
Slightly volatile
Asset Turnover11911341.0389
Slightly volatile

Mink Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap34.9 M36.8 M130.1 M
Slightly volatile
Enterprise Value31.7 M33.4 M97.2 M
Slightly volatile

Mink Fundamental Market Drivers

Cash And Short Term Investments3.4 M

Mink Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Mink Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Mink Therapeutics income statement, its balance sheet, and the statement of cash flows. Mink Therapeutics investors use historical funamental indicators, such as Mink Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Mink Therapeutics investors may use each financial statement separately, they are all related. The changes in Mink Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Mink Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Mink Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Mink Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue171.9 K152.8 K
Cost Of Revenue204.6 K194.4 K
Research And Ddevelopement To Revenue 0.01  0.01 
Revenue Per Share 72.29  75.91 
Ebit Per Revenue(0.01)(0.01)

Pair Trading with Mink Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mink Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mink Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mink Stock

  0.61VBIV VBI VaccinesPairCorr
The ability to find closely correlated positions to Mink Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mink Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mink Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mink Therapeutics to buy it.
The correlation of Mink Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mink Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mink Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mink Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Mink Stock Analysis

When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.